AE Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-11,907
| Closed | -$726K | – | 1317 |
|
|
2023
Q4 | $726K | Buy |
11,907
+6,540
| +122% | +$399K | ﹤0.01% | 1273 |
|
|
2023
Q3 | $244K | Sell |
5,367
-1,784
| -25% | -$81K | ﹤0.01% | 1697 |
|
|
2023
Q2 | $401K | Buy |
7,151
+2,582
| +57% | +$145K | ﹤0.01% | 1490 |
|
|
2023
Q1 | $207K | Buy |
+4,569
| New | +$207K | ﹤0.01% | 1725 |
|
|
2022
Q4 | – | Sell |
-4,810
| Closed | -$314K | – | 1823 |
|
|
2022
Q3 | $314K | Sell |
4,810
-537
| -10% | -$35.1K | ﹤0.01% | 1457 |
|
|
2022
Q2 | $325K | Buy |
5,347
+1,205
| +29% | +$73.2K | ﹤0.01% | 1404 |
|
|
2022
Q1 | $260K | Sell |
4,142
-1,323
| -24% | -$83K | ﹤0.01% | 1483 |
|
|
2021
Q4 | $414K | Sell |
5,465
-1,444
| -21% | -$109K | ﹤0.01% | 1332 |
|
|
2021
Q3 | $773K | Buy |
6,909
+1,943
| +39% | +$217K | 0.01% | 961 |
|
|
2021
Q2 | $804K | Buy |
4,966
+76
| +2% | +$12.3K | 0.01% | 911 |
|
|
2021
Q1 | $596K | Sell |
4,890
-9,772
| -67% | -$1.19M | 0.01% | 946 |
|
|
2020
Q4 | $2.25M | Buy |
14,662
+3,442
| +31% | +$527K | 0.03% | 464 |
|
|
2020
Q3 | $938K | Buy |
+11,220
| New | +$938K | 0.01% | 654 |
|
|
2020
Q2 | – | Sell |
-5,015
| Closed | -$213K | – | 1259 |
|
|
2020
Q1 | $213K | Buy |
+5,015
| New | +$213K | ﹤0.01% | 984 |
|